Rani Therapeutics develops orally administered biologics, including the RaniPill capsule, to replace subcutaneous or IV injection of biologics. Its product pipeline includes treatments for neuroendocrine tumors, psoriatic arthritis, osteoporosis, growth hormone deficiency, hypoparathyroidism, and type 2 diabetes. The company was founded in 2012 and is based in San Jose, California.